AQR Capital Management LLC Has $285,000 Stock Position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)

AQR Capital Management LLC lessened its holdings in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) by 84.2% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 11,700 shares of the biotechnology company's stock after selling 62,525 shares during the period. AQR Capital Management LLC's holdings in Arcturus Therapeutics were worth $285,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the business. CANADA LIFE ASSURANCE Co boosted its position in shares of Arcturus Therapeutics by 10.5% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 4,492 shares of the biotechnology company's stock worth $152,000 after acquiring an additional 428 shares in the last quarter. Hennion & Walsh Asset Management Inc. boosted its position in Arcturus Therapeutics by 2.5% in the first quarter. Hennion & Walsh Asset Management Inc. now owns 31,930 shares of the biotechnology company's stock valued at $1,078,000 after buying an additional 778 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its position in Arcturus Therapeutics by 5.7% in the first quarter. Price T Rowe Associates Inc. MD now owns 17,004 shares of the biotechnology company's stock valued at $575,000 after buying an additional 922 shares in the last quarter. Russell Investments Group Ltd. acquired a new stake in Arcturus Therapeutics in the first quarter valued at approximately $40,000. Finally, Public Employees Retirement System of Ohio boosted its position in Arcturus Therapeutics by 63.8% in the first quarter. Public Employees Retirement System of Ohio now owns 4,620 shares of the biotechnology company's stock valued at $156,000 after buying an additional 1,800 shares in the last quarter. Institutional investors and hedge funds own 94.54% of the company's stock.

Arcturus Therapeutics Price Performance

NASDAQ ARCT traded down $0.03 during mid-day trading on Thursday, reaching $20.60. 387,447 shares of the stock were exchanged, compared to its average volume of 478,549. Arcturus Therapeutics Holdings Inc. has a one year low of $17.52 and a one year high of $45.00. The stock has a 50 day simple moving average of $21.06 and a 200-day simple moving average of $25.53. The stock has a market cap of $554.80 million, a P/E ratio of -5.28 and a beta of 2.61.

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) last announced its earnings results on Monday, August 5th. The biotechnology company reported ($0.64) earnings per share for the quarter, topping analysts' consensus estimates of ($1.85) by $1.21. Arcturus Therapeutics had a negative net margin of 41.21% and a negative return on equity of 25.47%. The business had revenue of $49.86 million during the quarter, compared to the consensus estimate of $21.00 million. During the same quarter last year, the firm earned ($1.98) earnings per share. Sell-side analysts anticipate that Arcturus Therapeutics Holdings Inc. will post -2.6 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have weighed in on the stock. Leerink Partners began coverage on shares of Arcturus Therapeutics in a research report on Monday, August 12th. They issued an "outperform" rating and a $70.00 target price on the stock. HC Wainwright reaffirmed a "buy" rating and set a $63.00 price target on shares of Arcturus Therapeutics in a research note on Tuesday, October 1st. Leerink Partnrs raised shares of Arcturus Therapeutics to a "strong-buy" rating in a research note on Monday, August 12th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Arcturus Therapeutics in a research note on Monday, September 9th. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Buy" and an average target price of $71.40.

Insider Buying and Selling

In other Arcturus Therapeutics news, COO Pad Chivukula sold 12,000 shares of the firm's stock in a transaction on Tuesday, October 15th. The shares were sold at an average price of $20.76, for a total value of $249,120.00. Following the completion of the sale, the chief operating officer now directly owns 435,334 shares in the company, valued at approximately $9,037,533.84. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 13.80% of the stock is owned by insiders.

Arcturus Therapeutics Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.